

Docetaxel Q3w TAX 327 study

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



Docetaxel Q3w TAX 327 study

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer  
Experimental Arm: Docetaxel Q3w + Prednisone or prednisolone  
Control Arm: Mitoxantrone ± prednisone or prednisolone

